PHVSPharvaris N.V.

$37.04

$20.1252 weeks$37.29

Price

$37.04+82%1Y

1M+11%1Y+82%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value92

Quality33

Momentum78

Growth-

Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.

In the company’s own words · 20-F filed Apr 2, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$2.29B

1Y Return+82%

5Y Return+125%

Raw charts

2 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #45 of 145 by Smart Score

Compare peers

NRIX+16%

Nurix Therapeutics, Inc.

MLYS+2.2%

Mineralys Therapeutics, Inc.

BHVN+2.5%

Biohaven Ltd.

SLBT+12%

SL Science Holding Limited

MBX+4.1%

MBX Biosciences, Inc.

MRVI+6.2%

Maravai LifeSciences Holdings, Inc.